Drug intelligence / Profile preview

BIO-108

Development stage: Preclinical
Lead developer: BiOneCure Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BIO-108 is a preclinical-stage antibody-drug conjugate (ADC) being developed by BiOneCure Therapeutics for the treatment of solid tumors. As of early 2024, the specific biological target and mechanism of action for BIO-108 remain undisclosed. The drug is part of a pipeline of next-generation ADCs utilizing BiOneCure's proprietary payload platforms, which aim to provide a tailor-made approach to cancer therapy. The candidate is currently in the lead development phase, targeting various solid tumor indications.

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on BIO-108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-108.

Explore the full profile